Skip to main content

Table 2 Cost and outcome results in base-case analysis

From: Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis

Strategy

SG

TPC

SG vs. TPC

Cost, $

   

Cost of progression-free state

233,023

2251

230,772

Cost of post-progression state

4797

4191

606

Total cost

237,821

6442

231,378

QALM, month

   

QALM of progression-free state

7.19

3.19

3.99

QALM of post-progression state

5.10

3.93

1.17

Total QALM

12.29

7.12

5.17

ICER*, $/QALM

-

-

44,792

NMB

-198,641

16,269

-

INMB

-

-

-214,910

  1. *Compared to TPC at a willing-to-pay of $3188/QALM in China.
  2. Note: SG, Sacituzumab govitecan; TPC, single-agent treatment of physician’s choice; ICER, incremental cost-effectiveness ratio; QALM, quality adjusted life month; NMB, net monetary benefit; INMB, incremental net monetary benefit.